Previous 10 | Next 10 |
2023-09-06 12:31:59 ET More on Palisade Bio Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade Bio Financial information for Palisade Bio Palisade Bio fails in mid-stage trial for lead asset For further details s...
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 – Inflammatory bowel disease (IBD) represents a multi-billion dollar ...
2023-08-11 08:51:15 ET Palisade Bio press release ( NASDAQ: PALI ): Q2 GAAP EPS of -$0.53. As of June 30, 2023, the Company had cash and cash equivalents of $16.4 million, which includes proceeds from the $6.0 million registered direct offering and concurrent private place...
– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline – Strong financial position with cash to fund operations through 2024 Carlsbad, CA, Aug. 11, 2023 (GLOBE NEWSWI...
2023-08-09 13:27:46 ET Gainers: Benitec Biopharma ( BNTC ) +81% . Tango Therapeutics ( TNGX ) +77% . Decibel Therapeutics ( DBTX ) +76% . T Stamp ( IDAI ) +50% . Millennium Group International Holdings ( MGIH ) +43% . EBET ( ...
2023-08-09 10:08:11 ET Gainers: Tango Therapeutics ( TNGX ) +137% . Decibel Therapeutics ( DBTX ) +72% . Mirati Therapeutics ( MRTX ) +26% . Azenta ( AZTA ) +25% . Clover Health Investments ( CLOV ) +18 % . Losers: ...
2023-08-09 08:32:27 ET More on Palisade Bio Palisade Bio shares plummet following a $6M registered direct offering Palisade rises on upcoming EU patent linked to LB1148 for post-surgical abdominal adhesions Palisade Bio ends enrollment in mid-stage trial for lead can...
– Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery Carlsbad, CA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biophar...
Topline data expect ed in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced ...
PALISADES ANNOUNCES NEW FOUND MAKES NEW HIGH-GRADE, AT SURFACE DISCOVERY AT JACKPOT ZONE AT QUEENSWAY PROJECT Canada NewsWire VANCOUVER, BC , June 22, 2023 /CNW/ - Palisades Goldcorp Ltd. (TSX-V: PALI) (" Palisades " or the " Company ") is pleased to anno...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...